Synthetic inhibitors of thrombin and factor Xa: From bench to bedside

Thrombosis Research

Volumn 93, Issue 5, 1999, Pages 203-241

  Hauptmann, Jörg ^a   Stürzebecher, Jörg ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Effects; Factor Xa inhibitors; Pharmacokinetics; Structures; Therapeutic action; Thrombin inhibitors

Indexed keywords

1 (2 AMINO 6 METHYL 5 PYRIDINYLMETHYLAMINOCARBONYLMETHYL) 3 BENZYLSULFONAMIDO 6 METHYL 2 PYRIDINONE; 2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; 2,7 BIS(4 AMIDINOBENZYLIDINE)CYCLOHEPTAN 1 ONE; 3 BENZYLSULFONYLAMIDO 6 METHYLPYRIDIN 2 ONE ACETAMIDE 5 (2 AMINO 6 METHYLPYRIDINE); 4 METHOXY 2,3,6 TRIMETHYLSULFONYLASPARTYL DEXTRO (4 AMIDINOPHENYLALANINE)PIPERIDINE; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID; [N [4 [(1 ACETIMIDOYL 4 PIPERIDYL)OXY]PHENYL] N [(7 AMIDINO 2 NAPHTHYL)METHYL]SULFAMOYL]ACETIC ACID MONOMETHANE SULFATE; ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; ANTICOAGULANT AGENT; ARGATROBAN; ARGININE DERIVATIVE; BENZAMIDINE DERIVATIVE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; CRC 220; DEXTRO PHENYLALANYLPROLYLARGININAL; DEXTRO PHENYLPROLYLARGININE; EFEGATRAN; HEPARIN; HIRUDIN; INOGATRAN; L 371912; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; N (2 NAPHTHYLSULFONYL)GLYCYL 4 AMIDINOPHENYLALANINE PIPERIDIDE; N (9 HYDROXY 9 FLUORENECARBOXY)PROLINE (4 AMINOCYCLOHEXYLMETHYL)AMIDE; NAPSAGATRAN; SR 25477; THROMBIN; THROMBIN INHIBITOR; TOLUENESULFONYLGLYCYL(3 AMIDINOPHENYLALANYL)PIPERIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOSIS; TREATMENT INDICATION; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANTICOAGULANTS; ANTITHROMBINS; DRUG DESIGN; FACTOR XA; HUMANS; MODELS, MOLECULAR; THROMBIN;

EID: 0344629348     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00192-3     Document Type: Review

References (277)

1. Claeson G. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Blood Coagul Fibrinolysis. 5:1994;411-436.
2. Blombäck B. Fibrinogen and fibrin - proteins with complex roles in hemostasis and thrombosis. Thromb Res. 83:1996;1-75.
3. Das J., Kimball S.D. Thrombin active site inhibitors. Bioorg Med Chem. 3:1995;999-1007.
4. Maffrand J.P. Direct thrombin inhibitors. Nouv Rev Fr Hematol. 34:1992;405-419.
5. Kimball S.D. Thrombin active site inhibitors. Curr Pharm Des. 1:1995;441-468.
6. Lyle T.A. Small-molecule inhibitors of thrombin. Perspect Drug Discov Design. 1:1993;453-460.
7. Edmunds J.J., Rapundalo S.T., Siddiqui M.A. Thrombin and factor Xa inhibition. Ann Rep Med Chem. 31:1996;51-60.
8. Ripka W.C., Vlasuk G.P. Antithrombotics/Serine Proteases. Ann Rep Med Chem. 32:1997;71-89.
9. Wiley M.R., Fisher M.J. Small molecule direct thrombin inhibitors. Expert Opin Ther Patents. 7:1997;1265-1282.
10. Sanderson P.E.J., Naylor-Olsen A.M. Thrombin inhibitor design. Curr Med Chem. 5:1998;289-304.
11. Caflisch A., Walchli R., Ehrhardt C. Computer-aided design of thrombin inhibitors. News Physiol Sci. 13:1998;182-189.
12. Kimball S.D. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coagul Fibrinolysis. 6:1995;511-519.
13. Kaiser B., Hauptmann J. Pharmacology of synthetic thrombin inhibitors of the tripeptide type. Cardiovasc Drug Rev. 10:1992;71-78.
14. Tapparelli C., Metternich R., Ehrhardt C., Cook N.S. Synthetic low-molecular weight thrombin inhibitors. Molecular design and pharmacological profile Trends Pharmacol Sci. 14:1993;366-376.
15. Fitzgerald D. Specific thrombin inhibitors in vivo. Ann NY Acad Sci. 714:1994;41-52.
16. Balasubramanian B.N. Advances in the design and development of novel direct and indirect thrombin inhibitors. Bioorg Med Chem. 3:1995;999-1156.
17. Hauptmann J., Markwardt F. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Semin Thromb Hemost. 18:1992;200-217.
18. Ripka W.C. New thrombin inhibitors in cardiovascular disease. Curr Opin Chem Biol. 1:1997;242-253.
19. Bush L.R. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc Drug Rev. 9:1991;247-263.
20. Smith G.F., Gifford-Moore D., Craft T.J., Chirgadze N., Ruterbories K.J., Lindstrom T.D., Satterwhite J.H. Efegatran. A new cardiovascular anticoagulant Pifarre R. New anticoagulants for the cardiovascular patient. 1997;265-300 Hanley and Belfus, Philadelphia.
21. Schwarz R.P. The preclinical and clinical pharmacology of Novastan (argatroban). Pifarre R. New anticoagulants for the cardiovascular patient. 1997;231-249 Hanley and Belfus, Philadelphia.
22. Hursting M.J., Alfor K.L., Becker J.-C., Brooks R.L., Joffrion J.L., Knappenberger G.D., Kogan P.W., Kogan T.P., McKinney A.A., Schwarz R.P. Novastan® (brand of argatroban). A small molecule, direct thrombin inhibitor Semin Thromb Hemost. 23:1997;503-516.
23. Kaiser B., Hauptmann J. Factor Xa inhibitors as novel antithrombotic agents. Facts and perspectives Cardiovasc Drug Rev. 12:1994;225-236.
24. Mao S.-S. Factor Xa inhibitors. Perspect Drug Discov Design. 1:1993;423-430.
25. Boneu B. Anti-Xa molecules. Arch Mal Coeur Vaiss. 89:1996;1491-1494.
26. Al-Obeidi F., Ostrem J.A. Factor Xa inhibitors by classical and combinatorial chemistry. Drug Discov Today. 3:1998;223-231.
27. Tidwell R.R., Webster W.P., Shaver S.R., Geratz J.D. Strategies for anticoagulation with synthetic protease inhibitors. Xa inhibitiors versus thrombin inhibitors. Thromb Res. 19:1980;339-349.
28. Neeper M.P., Waxman L., Smith D.E., Schulman C.A., Sardana M., Ellis W.R., Schaffer L.W., Siegl P.K., Vlasuk G.P. Characterization of recombinant tick anticoagulant peptide. A highly selective inhibitor of blood coagulation factor Xa. J Biol Chem. 265:1990;17746-17752.
29. Nutt E.M., Jain D., Lenny A.B., Schaffer L., Siegl P.K., Dunwiddie C.T. Purification and characterization of recombinant antistasin. A leech-derived inhibitor of coagulation factor Xa Arch Biochem Biophys. 285:1991;37-44.
30. Bode W., Turk D., Karshikov A. The refined 1.9-Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin. Structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships Protein Sci. 1:1992;426-471.
31. Semple J.E., Rowley D.C., Brunck T.K., Ha-Uong T., Minami N.K., Owens T.D., Tamura S.Y., Goldman E.A., Siev D.V., Ardecky R.J., Carpenter S.H., Ge Y., Richard B.M., Nolan T.G., Håkanson K., Tulinsky A., Nutt R.F., Ripka W.C. Design, synthesis and evolution of a novel, selective, and orally bioavailable class of thrombin inhibitors. P1-argininal derivatives incorporating P3-P4 lactam sulfonamide moieties J Med Chem. 39:1996;4531-4536.
32. Wiley M.R., Chirgadze N.Y., Clawson D.K., Craft T.J., Gifford-Moore D.S., Jones N.D., Olkowski J.L., Weir L.C., Smith G.F. D-Phe-Pro-p-amidinobenzylamine. A potent and highly selective thrombin inhibitor Bioorg Med Chem Lett. 6:1996;2387-2392.
33. Feng D.-M., Gardell S.J., Lewis S.D., Bock M.G., Chen Z., Freidinger R.M., Naylor-Olsen A.M., Ramjit H.G., Woltmann R., Baskin E.P., Lynch J.J., Lucas R., Shafer J.A., Dancheck K.B., Chen I.W., Mao S.S., Krueger J.A., Hare T.R., Mulichak A.M., Vacca J.P. Discovery of a novel, selective, and orally bioavailable class of thrombin inhibitors incorporating amidinopyridyl moieties at the P1 position. J Med Chem. 40:1997;3726-3733.
34. Fevig J.M., Buriak J., Cacciola J., Alexander R.S., Kettner C.A., Knabb R.M., Pruitt J.R., Weber P.C., Wexler R.R. Rational design of boropeptide thrombin inhibitors. β, β-dialkylphenylethylglycine P2 analogs of DuP 714 with greater selectivity over complement factor 1 and an improved safety profile Bioorg Med Chem Lett. 8:1998;301-306.
35. Sall D.L., Bastian J.A., Briggs S.L., Buben J.A., Chirgadze N.Y., Clawson D.K., Denney M.L., Giera D.D., Gifford-Moore D.S., Harper R.W., Hauser K.L., Klimkowski V.J., Kohn T.J., Lin H.-S., McCowan J.R., Palkowitz A.D., Smith G.F., Takeuchi K., Thrasher K.J., Tinsley J.M., Utterback B.G., Yan S.-C.B., Zhang M. Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships, and binding orientation. J Med Chem. 40:1997;3489-3493.
36. Lyle T.A., Chen Z.G., Appleby S.D., Freidinger R.M., Gardell S.J., Lewis S.D., Li Y., Lyle E.A., Lynch J.J., Mulichak A.M., Ng A.S., Naylor-Olsen A.M., Sanders W.M. Synthesis, evaluation, and crystallographic analysis of L-371, 912. A potent and selective active-site thrombin inhibitor Bioorg Med Chem Lett. 7:1997;67-72.
37. Brady S.F., Stauffer K.J., Lumma W.C., Smith G.M., Ramjit H.G., Lewis S.D., Lucas B.J., Gardell S.J., Lyle E.A., Appleby S.D., Cook J.J., Holahan M.A., Stranieri M.T., Lynch J.J., Lin J.H., Chen I.W., Vastag K., Naylor-Olsen A.M., Vacca J.P. Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy)prolyl trans-4-aminocyclohexylmethyl amide (L-372,460). Coapplication of structure-based design and rapid multiple analogue synthesis on solid support J Med Chem. 41:1998;401-406.
38. Weber I.R., Neidlein R., Von der Saal W., Grams F., Leinert H., Strein K., Engh R.A., Kucznierz R. Diarylsulfonamides as selective, non-peptidic thrombin inhibitors. Bioorg Med Chem Lett. 8:1998;1613-1618.
39. Hilpert K., Ackermann J., Banner D.W., Gast A., Gubernator K., Hadvary P., Labler L., Müller K., Schmid G., Tschopp T.B., Van de Waterbeemd H. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem. 37:1994;3889-3901.
40. Tucker T.J., Lumma W.C., Mulichak A.N., Chen Z., Naylor-Olsen A.M., Lewis S.D., Lucas R., Freidinger R.M., Kuo L.C. Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site. J Med Chem. 40:1997;830-832.
41. Skordalakes E., Tyrell R., Elgendy S., Goodwin C.A., Green D., Dodson G., Scully M.F., Freyssinet J.-M.H., Kakkar V.V., Deadman J.J. Crystallographic structures of human α-thrombin complexed to peptide boronic acids lacking a positive charge at P1. Evidence of novel interactions. J Am Chem Soc. 119:1997;9935-9936.
42. Lumma W.C., Witherup K.M., Tucker T.J., Brady S.F., Sisko J.T., Naylor-Olsen A.M., Lewis S.D., Lucas B.J., Vacca J.P. Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures. Rapid structure-activity studies by solid-phase synthesis J Med Chem. 41:1998;1011-1013.
43. Brandstetter H., Turk D., Hoeffken H.W., Grosse D., Stürzebecher J., Martin P.D., Edwards B.F.P., Bode W. Refined 2.3 Ångström X-ray crystal structure of bovine thrombin complex formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA - a starting point for improving antithrombotics. J Mol Biol. 226:1992;1085-1099.
44. Banner D.W., Hadvary P. Crystallographic analysis at 3.0 A resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem. 266:1991;20085-20093.
45. Bode W., Turk D., Stürzebecher J. Geometry of binding of the benzamidine- and arginine-based inhibitors NAPAP and MQPA to human α-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur J Biochem. 193:1990;175-182.
46. Banner D.W., Hadvary P. Inhibitor binding to thrombin. X-ray crystallographic studies Adv Exp Med Biol. 340:1993;27-33.
47. Bajusz S., Szell E., Bagdy D., Barabas E., Horvath G., Dioszegi M., Fittler Z., Szabo G., Juhasz A., Tomori E., Szilagy G. Highly active and selective anticoagulants. D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H J Med Chem. 33:1990;1729-1735.
48. Kettner C., Knabb R.M. Peptide boronic acid inhibitors of thrombin. Adv Exp Med Biol. 340:1993;109-118.
49. Balasubramanian N., St Laurent D.R., Federici M.E., Meanwell N.A., Wright J.J., Schumacher W.A., Seiler S.M. Active site-directed synthetic thrombin inhibitors. Synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series J Med Chem. 36:1993;300-303.
50. Shuman R.T., Rothenberger R.B., Campbell C.S., Smith G.F., Gifford-Moore D.S., Paschal J.W., Gesellchen P.D. Structure-activity study of tripeptide thrombin inhibitors using α-alkyl amino acids and other conformationally constrained amino acid substitutions. J Med Chem. 38:1995;4446-4453.
51. Kaiser B., Richter M., Hauptmann J., Markwardt F. Anticoagulant and antithrombotic action of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile. Pharmazie. 46:1991;128-131.
52. Tapparelli C., Metternich R., Ehrhardt C., Zurini M., Claeson G., Scully M.F., Stone S.R. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem. 268:1993;4734-4741.
53. Rupin A., Mennecier P., Lila C., de Nanteuil G., Verbeuren T.J. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor. Thromb Haemost. 78:1997;1221-1227.
54. Cacciola J., Fevig J.M., Alexander R.S., Brittelli D.R., Kettner C.A., Knapp R.M., Weber P.C. Synthesis of conformationally-restricted boropeptide thrombin inhibitors. Bioorg Med Chem Lett. 6:1996;301-306.
55. Lee S.L., Alexander R.S., Smallwood A., Trievel R., Mersinger L., Weber P.C., Kettner C. New inhibitors of thrombin and other trypsin-like proteases. Hydrogen bonding of an aromatic cyano group with a backbone amide of the P1 binding site replaces binding of a basic side chain Biochemistry. 36:1997;13180-13186.
56. Deadman J.J., Elgendy S., Goodwin C.A., Green D., Baban J.A., Patel G., Skordalakes E., Chino N., Claeson G., Kakkar V.V., Scully M.F. Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J Med Chem. 38:1995;1511-1522.
57. Lewis S.D., Ng A.S., Lyle E.A., Mellott M.J., Appleby S.D., Brady S.F., Stauffer K.J., Sisko J.T., Mao S., Veber D.F., Nutt R.F., Lynch J.J., Cook J.J., Gardell S.J., Shafer J.A. Inhibition of thrombin by peptides containing lysyl-α-keto carbonyl derivatives. Thromb Haemost. 74:1995;1107-1112.
58. Wiley M.R., Chirgadze N., Clawson D.K., Craft T.J., Gifford-Moore D.S., Jones N.D., Olkowski J.L., Schacht A.L., Weir L.C., Smith G.F. Serine protease selectivity of the thrombin inhibitor D-Phe-Pro-agmatine and its homologs. Bioorg Med Chem Lett. 5:1995;2835-2840.
59. Tucker T.J., Lumma W.C., Lewis S.D., Gardell S.J., Lucas B.J., Baskin E.P., Woltmann R., Lynch J.J., Lyle E.A., Appleby S.D., Chen I.W., Dancheck K.B., Vacca J.P. Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. J Med Chem. 40:1997;1565-1569.
60. Tucker T.J., Lumma W.C., Lewis S.D., Gardell S.J., Lucas B.J., Sisko J.T., Lyle E.A., Baskin E.P., Woltmann R.F., Appleby S.D., Chen I.W., Dancheck K.B., Naylor-Olsen A.M., Krueger J.A., Cooper C.M., Vacca J.P. Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position. J Med Chem. 40:1997;3687-3693.
61. Sanderson P.E.J., Cutrona K.J., Dorsey B.D., Dyer D.L., Mcdonough C.M., Naylor-Olsen A.M., Chen I.W., Chen Z.G., Cook J.J., Gardell S.J., Krueger J.A., Lewis S.D., Lin J.H., Lucas B.J., Lyle E.A., Lynch J.J., Stranieri M.T., Vastag K., Shafer J.A., Vacca J.P. L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor. Bioorg Med Chem Lett. 8:1998;817-822.
62. Dickneite G., Seiffge D., Diehl K.H., Reers M., Czech J., Weinmann E., Hoffmann D., Stüber W. Pharmacological characterization of a new 4-amidinophenylalanine thrombin-inhibitor (CRC 220). Thromb Res. 77:1995;357-368.
63. Kim S., Hwang S.Y., Kim Y.K., Yun M., Oh Y.S. Rational design of selective thrombin inhibitors. Bioorg Med Chem Lett. 7:1997;769-774.
64. Böhm H.J., Klebe G., Kubinyi H. Wirkstoffdesign. 1996;Spektrum, Heidelberg-Berlin-Oxford. pp. 473-81.
65. Kim S.W., Hong C.Y., Lee K., Lee E.J., Koh J.S. Solid phase synthesis of benzylamine-derived sulfonamide library. Bioorg Med Chem Lett. 8:1998;735-738.
66. Kim S.W., Hong C.Y., Koh J.S., Lee E.J., Lee K. Solid phase synthesis of benzamidine-derived sulfonamide libraries. Mol Diversity. 3:1998;133-136.
67. Schumacher W.A., Balasubramanian N., St Laurent D.R., Seiler S.M. Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis. Eur J Pharmacol. 259:1994;165-171.
68. Grootenhuis P.D.J., Van Galen P.J.M. Correlation of binding affinities with non-bonded interaction energies of thrombin-inhibitor complexes. Acta Crystallogr. D51:1995;560-566.
69. Apostolakis J., Pluckthun A., Caflisch A. Docking small ligands in flexible binding sites. J Comput Chem. 19:1998;21-37.
70. Westhead D.R., Clark D.E., Murray C.W. A comparison of heuristic search algorithms for molecular docking. J Comput-Aided Mol Design. 11:1997;209-228.
71. Stürzebecher J., Prasa D., Hauptmann J., Wikström P., Vieweg H. Synthesis and structure-activity relationships of potent thrombin inhibitors. Piperazides of 3-amidinophenylalanine J Med Chem. 40:1997;3091-3099.
72. Oh Y.S., Yun M., Hwang S.Y., Hong S., Shin Y., Lee K., Yoon K.H., Yoo Y.J., Kim D.S., Lee S.H., Lee Y.H., Park H.D., Lee C.H., Lee S.K., Kim S. Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor. Bioorg Med Chem Lett. 8:1998;631-634.
73. Malikayil J.A., Burkhart J.P., Schreuder H.A., Broersma R.J., Tardif C., Kutcher L.W., Mehdi S., Schatzman G.L., Neises B., Peet N.P. Molecular design and characterization of an α-thrombin inhibitor containing a novel P1 moiety. Biochemistry. 36:1997;1034-1040.
74. 1 heterocyclic thrombin inhibitors. Bioorg Med Chem Lett. 7:1997;79-84.
75. Cutrona K.J., Sanderson P.E.J. The synthesis of thrombin inhibitor L-370,518 via an α-hydroxy-β-lactam. Tetrahedron Lett. 37:1996;5045-5048.
76. Misra R.N., Kelly Y.F., Brown B.R., Roberts D.G.M., Chong S., Seiler S.M. Argatroban analogs. Synthesis, thrombin inhibitory activity and cell permeability of aminoheterocyclic guanidine surrogates Bioorg Med Chem Lett. 4:1994;2165-2170.
77. Kim K.S., Moquin R.V., Quian L.G., Morrison R.A., Seiler S.M., Roberts D.G.M., Ogletree M.L., Youssef S., Chong S. Preparation of argatroban analog thrombin inhibitors with reduced basic guanidine moiety, and studies of their permeability and antithrombotic activities. Med Chem Res. 6:1996;377-383.
78. Iwanowicz E.J., Lau W.F., Lin J., Roberts D.G.M., Seiler S.M. Retro-binding tripeptide thrombin active-site inhibitors. Discovery, synthesis, and molecular modeling J Med Chem. 37:1994;2122-2124.
79. Claeson G., Philipp M., Agner E., Scully M.F., Metternich R., Kakkar V.V., Desoyza T., Niu L.H. Benzyloxycarbonyl-D-Phe-Pro-methoxy-propylglycine - a novel inhibitor of thrombin with high selectivity containing a neutral side chain at the P1 position. Biochem J. 290:1993;309-312.
80. Von der Saal W., Kucznierz R., Leinert H., Engh R.A. Derivatives of 4-amino-pyridine as selective thrombin inhibitors. Bioorg Med Chem Lett. 7:1997;1283-1288.
81. Weber P.C., Lee S.L., Lewandowski F.A., Schadt M.C., Chang C.H., Kettner C.A. Kinetic and crystallographic studies of thrombin with Ac-(d)Phe-Pro-boroArgOH and its lysine, amidine, homolysine, and ornithine analogs. Biochemistry. 34:1995;3750-3757.
82. Steinmetzer T, Batdorsdhjin M, Kleinwächter P, Seyfarth L, Greiner G, Reissmann S, Stürzebecher J. New thrombin inhibitors based on D-Cha-Pro-derivatives. J Enzyme Inhibit. In press 1999.
83. Tucker T.J., Brady S.F., Lumma W.C., Lewis S.D., Gardell S.J., Naylor-Olsen A.M., Yan Y., Sisko J.T., Stauffer K.J., Lucas B.J., Lynch J.J., Cook J.J., Stranieri M.T., Holahan M.A., Lyle E.A., Baskin E.P., Chen I.W., Dancheck K.B., Krueger J.A., Cooper C.M., Vacca J.P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J Med Chem. 41:1998;3210-3219.
84. Bone R., Lu T., Illig C.R., Soll R.M., Spurlino J.C. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes. J Med Chem. 41:1998;2068-2075.
85. Isaacs R.C.A., Cutrona K.J., Newton C.L., Sanderson P.E.J., Solinsky M.G., Baskin E.P., Chen I.W., Cooper C.M., Cook J.J., Gardell S.J., Lewis S.D., Lucas R.J., Lyle E.A., Lynch J.J., Naylor-Olsen A.M., Stranieri M.T., Vastag K., Vacca J.P. C6 modification of the pyridinone core of thrombin inhibitor L-374,087 as a means of enhancing its oral absorption. Bioorg Med Chem Lett. 8:1998;1719-1724.
86. Lee K., Hwang S.Y., Hong S., Hong C.Y., Lee C.S., Shin Y., Kim S., Yun M., Yoo Y.J., Kang M., Oh Y.S. Structural modification of an orally active thrombin inhibitor, LB30057. Replacement of the D-pocket-binding naphthyl moiety Bioorg Med Chem Lett. 6:1998;869-876.
87. Lin Z., Johnson M.E. Proposed cation-π mediated binding by factor Xa. A novel enzymatic mechanism for molecular recognition FEBS Lett. 370:1995;1-5.
88. Stubbs M.T. Structural aspects of factor Xa inhibition. Curr Pharm Design. 2:1996;543-552.
89. Brandstetter H., Kuhne A., Bode W., Huber R., von der Saal W., Wirthensohn K., Engh R.A. X-Ray structure of active site-inhibited clotting factor Xa - implications for drug design and substrate recognition. J Biol Chem. 271:1996;29988-29992.
90. Katakura S., Nagahara T., Hara T. Molecular model of interaction between factor Xa and DX-9065a, a novel factor Xa inhibitor. Contribution of the acetimidoylpyrrolidine moiety of the inhibitor to potency and selectivity for serine proteases Eur J Med Chem. 30:1995;387-394.
91. Padmanabhan K., Padmanabhan K.P., Tulinsky A., Park C.H., Bode W., Huber R., Blankenship D.T., Cardin A.D., Kisiel W. Structure of human des (1-45) factor Xa at 2.2 Ångstrom resolution. J Mol Biol. 232:1993;947-966.
92. Stubbs M.T., Huber R., Bode W. Crystal structures of factor Xa specific inhibitors in complex with trypsin. Structural grounds for inhibition of factor Xa and selectivity against thrombin FEBS Lett. 375:1995;103-107.
93. Fraternali F., Do Q.T., Doan B.T., Atkinson R.A., Palmas P., Sklenar V., Safar P., Wildgoose P., Strop P., Saudek V. Mapping the active site of factor Xa by selective inhibitors. An NMR and MD study Proteins. 30:1998;264-274.
94. Kamata K., Kawamoto H., Honma T., Iwama T., Kim S.H. Structural basis for chemical inhibition of human blood coagulation factor Xa. Proc Natl Acad Sci USA. 95:1998;6630-6635.
95. Vaz R.J., McLean L.R., Pelton J.T. Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)- 1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-amidino-2-naphthyl)propanoic acid hydrochloride and some analogs to Factor Xa using a comparative molecular field analysis. J Comput-Aided Mol Design. 12:1998;99-110.
96. Hollenbach S., Sinha U., Lin P.-H., Needham K., Frey K., Hancock T., Wong A., Wolf D. A comparative study of prothrombinase and thrombin inhibitors in a novel rabbit model of non-occlusive deep vein thrombosis. Thromb Haemost. 71:1994;357-362.
97. Prasa D., Svendsen L., Stürzebecher J. Inhibition of thrombin generation in plasma by inhibitors of factor Xa. Thromb Haemost. 78:1997;1215-1219.
98. Stürzebecher J., Stürzebecher U., Vieweg H., Wagner G., Hauptmann J., Markwardt F. Synthetic inhibitors of bovine factor Xa and thrombin. Comparison of their anticoagulant efficiency. Thromb Res. 54:1989;245-252.
99. Hauptmann J., Kaiser B., Nowak G., Stürzebecher J., Markwardt F. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors. Thromb Haemost. 63:1990;220-223.
100. Hauptmann J., Kaiser B. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro. Blood Coagul Fibrinolysis. 4:1993;577-582.
101. Shaw K.J., Guilford W.J., Dallas J.L., Koovakkaat S.K., McCarrick M.A., Liang A., Light D.R., Morrissey M.M. Z,Z)-2,7-Bis(4-amidinobenzylidene)cycloheptan-1-one. Identification of a highly active inhibitor of blood coagulation factor Xa J Med Chem. 41:1998;3551-3556.
102. Lloyd A.L. Factor Xa inhibitors. Drug Discov Today. 3:1998;141.
103. Wong P.C., Crain Jr E.J., Nguan O., Watson C.A., Racanelli A. Antithrombotic actions of selective inhibitors of blood coagulation factor Xa in rat models of thrombosis. Thromb Res. 83:1996;117-126.
104. Yokoyama T., Kelly A.B., Marzec U.M., Hanson S.R., Kunitada S., Harker L.A. Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates. Circulation. 92:1995;485-491.
105. Hara T., Yokoyama A., Ishihara H., Yokoyama Y., Nagahara T., Iwamoto M. DX-9065a, a new synthetic, potent anticoagulant and selective inhibitor of factor Xa. Thromb Haemost. 71:1994;314-319.
106. Hara T., Yokoyama T., Tanabe K., Ishihara H., Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost. 74:1995;635-639.
107. Herbert J.M., Bernat A., Dol F., Herault J.P., Crepon B., Lormeau J.C. DX 9065a, a novel, synthetic, selective and orally active inhibitor of factor Xa. In vitro and in vivo studies J Pharmacol Exp Ther. 276:1996;1030-1038.
108. Katakura S., Nagahara T., Hara T., Iwamoto M. A novel factor Xa inhibitor. Structure-activity relationships and selectivity between factor Xa and thrombin Biochem Biophys Res Commun. 197:1993;965-972.
109. Nagahara T., Yokoyama T., Inamura K., Katakura S., Komoriya S., Yamaguchi H., Hara T., Iwamoto M. Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. J Med Chem. 37:1994;1200-1207.
110. Hara T., Yokoyama A., Morishima Y., Kunitada S. Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res. 80:1995;99-104.
111. Nagahara T., Katakura S., Yokoyama Y., Kanaya N., Inamura K., Komoriya S., Yamada K., Yamaguchi H., Tanabe K., Morishima Y., Ishihara H., Hara T., Yamazaki K., Kunitada S., Iwamoto M. Design, synthesis and biological activities of orally active coagulation factor Xa inhibitors. Eur J Med Chem. 30:1995;140s-143s.
112. Yamazaki M., Asakura H., Aoshima K., Saito M., Jokaji H., Uotani C., Kumabashiri I., Morishita E., Ikeda T., Matsuda T. Effects of DX-9065a, an orally active, newly synthesized and specific inhibitor of factor Xa, against experimental disseminated intravascular coagulation in rats. Thromb Haemost. 72:1994;393-396.
113. Kaiser B. A survey of anti-Xa-based drugs. Potential use in cardiovascular indications Pifarre R. New anticoagulants for the cardiovascular patient. 1997;431-441 Hanley and Belfus, Philadelphia.
114. Kehr C., Neidlein R., Engh R.A., Brandstetter H., Kucznierz R., Leinert H., Marzenell K., Strein K., von der Saal W. A short synthesis of the factor-Xa inhibitor DX-9065a using palladium-catalyzed key steps. Helvetica Chimica Acta. 80:1997;892-896.
115. Herault J.P., Bernat A., Pflieger A.M., Lormeau J.C., Herbert J.M. Comparative effects of two direct and indirect factor Xa inhibitors on free and clot-bound prothrombinase. J Pharmacol Exp Ther. 283:1997;16-22.
116. Morishima Y., Tanabe K., Terada Y., Hara T., Kunitada S. Antithrombotic and haemorrhagic effects of DX 9065a, a direct and selective factor Xa inhibitor. Comparison with a direct thrombin inhibitor and antithrombin III dependent anticoagulants Thromb Haemost. 78:1997;1366-1371.
117. Kawasaki T., Sato K., Sakai Y., Hurayama F., Koshio H., Taniuchi Y., Matsumoto Y. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb Haemost. 79:1998;410-416.
118. Yamashita T., Tsuji T., Matsuoka A., Giddings J.C., Yamamoto J. The antithrombotic effect of synthetic low molecular weight human factor Xa inhibitor, DX-9065a, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res. 85:1997;45-51.
119. Yamazaki M., Asakura H., Aoshima K., Saito M., Jokaji H., Uotani C., Kumabashiri I., Morishita E., Ikeda T., Matsuda T. Protective effects of DX-9065a, an orally active, novel synthesized and selective inhibitor of factor Xa, against thromboplastin-induced experimental disseminated intravascular coagulation in rats. Semin Thromb Hemost. 22:1996;255-259.
120. Kim D.I., Kambayashi J., Shibuya T., Sakon M., Kawasaki T. In vivo evaluation of DX-9065a, a synthetic factor Xa inhibitor, in experimental vein graft. J Atheroscler Thromb. 2:1996;110-116.
121. Nakata M., Kanekura S., Maruyama I. DX9065a, an Xa inhibitor, inhibits prothrombin-induced A549 lung adenocarcinoma cell proliferation. Cancer Lett. 122:1998;127-133.
122. Sato K., Kawasaki T., Taniuchi Y., Hirayama F., Koshio H., Matsumoto Y. YM-60828, a novel factor Xa inhibitor. Separation of its antithrombotic effects from its prolongation of bleeding time Eur J Pharmacol. 339:1997;141-146.
123. Sato K., Kawasaki T., Hisamichi N., Taniuchi Y., Hirayama F., Koshio H., Matsumoto Y. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br J Pharmacol. 123:1998;92-96.
124. Taniuchi Y., Sakai Y., Hisamichi N., Kayama M., Mano Y., Sato K., Hirayama F., Koshio H., Matsumoto Y., Kawasaki T. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human factor Xa. Thromb Haemost. 79:1998;543-548.
125. Quan M.L., Pruitt J.R., Ellis C.D., Liauw A.Y., Galemmo R.A., Stouten P.F.W., Wityak J., Knabb R.M., Thoolen M.J., Wong P.C., Wexler R.R. Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors. Bioorg Med Chem Lett. 7:1997;2813-2818.
126. Maduskuie T.P., McNamara K.J., Ru Y., Knabb R.M., Stouten P.F.W. Rational design and synthesis of novel, potent bis-phenylamidine carboxylate factor Xa inhibitors. J Med Chem. 41:1998;53-62.
127. Ostrem J.A., Al-Obeidi F., Safar P., Safarova A., Stringer S.K., Patek M., Cross M.T., Spoonamore J., LoCascio J.C., Kasireddy P., Thorpe D.S., Sepetov N., Lebl M., Wildgoose P., Strop P. Discovery of a novel, potent, and specific family of factor Xa inhibitors via combinatorial chemistry. Biochemistry. 37:1998;1053-1059.
128. Mohan R., Yun W.Y., Buckman B.O., Liang A., Trinh L., Morrissey M.M. Solid-phase synthesis of N-substituted amidinophenoxy pyridines as factor Xa inhibitors. Bioorg Med Chem Lett. 8:1998;1877-1882.
129. Phillips G.B., Buckman B.O., Davey D.D., Eagen K.A., Guilford W.J., Hinchman J., Ho E., Koovakkat S. Discovery of N-[2-[5-[Amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1- methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834). A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa J Med Chem. 41:1998;3557-3562.
130. Rupin A., Mennecier P., de Nanteuil G., Laubie M., Verbeuren T.J. A screening procedure to evaluate the anticoagulant activity and the kinetic behaviour of direct thrombin inhibitors. Thromb Res. 78:1995;217-225.
131. Elg M., Gustafsson D., Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost. 78:1997;1286-1292.
132. Lewis S.D., Lucas B.J., Brady S.F., Sisko J.T., Cutrona K.J., Sanderson P.E.J., Freidinger R.M., Mao S.S., Gardell S.J., Shafer J.A. Characterization of the two-step pathway for inhibition of thrombin by a-ketoamide transition state analogs. J Biol Chem. 273:1998;4843-4854.
133. Nilsson T., Sjöling-Ericksson A., Deinum J. The mechanism of binding of low-molecular-weight active site inhibitors to human α-thrombin. J Enzyme Inhibit. 13:1998;11-29.
134. Geratz J.D. Growth retardation and pancreatic enlargement in rats due to p-aminobenzamidine. Am J Path. 214:1968;595-600.
135. Teger-Nilsson A.-C., Bylund R., Gustafsson D., Gyzander E., Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res. 85:1997;133-145.
136. Barabas E., Szell E., Bajusz S. Screening for fibrinolysis inhibitory effect of synthetic thrombin inhibitors. Blood Coagul Fibrinolysis. 4:1993;243-248.
137. Callas D., Bacher P., Iqbal O., Hoppensteadt D., Fareed J. Fibrinolytic compromise by simultaneous administration of site-directed inhibitors of thrombin. Thromb Res. 74:1994;193-205.
138. Mor A., Mailard J., Favreau C., Reboud-RavauxM Reaction of thrombin and proteinases of the fibrinolytic system with a mechanism-based inhibitor, 3,4-dihydro-3-benzyl-6-chloromethyl-coumarin. Biochim Biophys Acta. 1038:1990;119-124.
139. Lenfors S., Gustafsson D. New model for in vivo studies of pharmacological intervention with endogenous fibrinolysis. Effects of thrombin inhibitors Semin Thromb Hemost. 22:1996;335-342.
140. Gustafsson D., Antonsson T., Bylund R., Eriksson U., Gyzander E., Nilsson I., Elg M., Mattsson C., Deinum J., Pehrsson S., Karlsson O., Nilsson A., Sörensen H. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost. 79:1998;110-118.
141. Callas D.D., Iqbal O., Hoppensteadt D., Fareed J. Fibrinolytic compromise by synthetic and recombinant thombin inhibitors. Implications in the treatment of thrombotic disorders Clin Appl Thromb/Hemost. 1:1995;114-124.
142. Callas D.D., Fareed J. Direct inhibition of protein Ca by site directed thrombin inhibitors. Implications in anticoagulant and thrombolytic therapy Thromb Res. 78:1995;457-460.
143. Prasa D., Svendsen L., Stürzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost. 77:1997;498-503.
144. Jackson C.V., Satterwhite J., Roberts E. Preclinical and clinical pharmacology of efegatran (LY294468). A novel antithrombin for the treatment of acute coronary syndromes Clin Appl Thromb/Hemost. 2:1996;258-267.
145. Kirchhofer D., Tschopp T.B., Hadvary P., Baumgartner H.R. Endothelial cells stimulated with tumor necrosis factor-α express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest. 93:1994;2073-2083.
146. Gast A., Tschopp T.B., Schmid G., Hilpert K., Ackermann J. Inhibition of clot-bound and free (fluid phase) thrombin by a novel synthetic inhibitor of thrombin (Ro 46-6240), recombinant hirudin and heparin in human plasma. Blood Coagul Fibrinolysis. 5:1994;879-887.
147. Lunven C., Gauffeny C., Lecoffre C., O'Brien D.P., Roome N.O., Berry C.N. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost. 75:1996;154-160.
148. Berry C.N., Girardot C., Lecoffre C., Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin.
149. Weitz J.I., Leslie B., Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inactivation by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 97:1998;544-552.
150. Gast A., Tschopp T.B., Baumgartner H.R. Thrombin plays a key role in late platelet thrombus growth and/or stability. Effect of a specific thrombin inhibitor on thrombogenesis induced by aortic subendothelium exposed to flowing rabbit blood. Arterioscler Thromb. 14:1994;1466-1474.
151. Chiu A.T., Mousa S.A., Pease L.J., Roscoe W.A., Bozarth J.M., Reilly T.M., Timmermans P.B.M.W.M. Inhibition of the thrombin-platelet reactions by DuP 714. Biochem Biophys Res Commun. 179:1991;1500-1508.
152. Kaiser B., Koza M., Walenga J.M., Fareed J. Flow cytometric evaluation of the effect of various thrombin inhibitors on platelet activation in whole blood. Thromb Res. 82:1996;257-263.
153. Reilly T.M., Knabb R.M., Hassell S.M., Bozarth J.M., Forsythe M.S., Mayo M.C., Racanelli A.L., Mousa S.A. Effect of thrombin inhibitors on platelet functions. Comparative analysis of DuP 714 and hirudin Blood Coagul Fibrinolysis. 3:1992;513-517.
154. Packham M.A., Bryant N.I., Guccione M.A. Agglutination of rabbit platelets in plasma by the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Thromb Haemost. 63:1990;282-285.
155. Kawai H., Yamamoto T., Hara H., Tamao Y. Inhibition of factor Xa-induced platelet aggregation by a selective thrombin inhibitor, argatroban. Thromb Res. 74:1994;185-191.
156. Horne W.C., Anderson G.M., Cohen D.J. Reproducibility and temporal stability of ADP-induced platelet aggregation. comparison of the anticoagulants sodium citrate and D-phenylalanyl-L-prolyl-L-arginyl-chloromethyl ketone Am J Hematol. 38:1991;48-53.
157. Scott N.A., Nunes G.L., King S.B. III, Harker L.A., Hanson S.R. Local delivery of an antithrombin inhibits platelet-dependent thrombosis. Circulation. 90:1994;1951-1955.
158. FitzGerald G.A., Shipp E. Antiplatelet and anticoagulant drugs in coronary vascular disease. Ann Epidemiol. 2:1992;529-542.
159. Liu J.T., Paul W., Emerson M., Cicala C., Page C.P. Thrombin inhibitors and anti-coagulants on thrombin-induced embolisation in rabbit cranial vasculature. Eur J Pharmacol. 264:1994;183-190.
160. Chiu P.J., Tetzloff G.G., Foster C., Chintala M., Sybertz E.J. Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs. Eur J Pharmacol. 321:1997;129-135.
161. Badimon J.J., Weng D., Chesebro J.H., Fuster V., Badimon L. Platelet deposition induced by severly damaged vessel wall is inhibited by a boroarginine synthetic peptide with antithrombin activity. Thromb Haemost. 71:1994;511-516.
162. Xiao Z.H., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97:1998;251-256.
163. Evstigneeva R.P., Kubatiev A.A., Tkachenko S.B., Zheltukhina G.A. Hydrochloride of peptide Boc-Gly-Pro-Arg-OMe - a selective inhibitor of thrombin- and epinephrine-induced platelet aggregation (Russ). Dokl Akad Nauk. 337:1994;680-682.
164. Kawano M., Watanabe S., Sasaki Y., Giddings J.C., Yamamoto J. Adjuvant effect of argatroban on staphylokinase induced thrombolysis of platelet rich thrombi in rat mesenteric venules in vivo. Thromb Res. 86:1997;115-126.
165. Hauptmann J. Degradation of a benzamidine-type synthetic inhibitor of coagulation enzymes in plasma of various species. Thromb Res. 61:1991;279-284.
166. Tomaru T., Nakamura F., Fujimori Y., Omata M., Kawai S., Okada R., Murata Y., Uchida Y. Local treatment with antithrombotic drugs can prevent thrombus formation. An angioscopic and angiographic study J Am Coll Cardiol. 26:1995;1325-1332.
167. Imanishi T., Arita M., Hamada M., Tomobuchi Y., Hano T., Nishio I. Effects of locally administration of argatroban using a hydrogel-coated balloon catheter on intimal thickening induced by balloon injury. Jpn Circ J. 61:1997;256-262.
168. Imanishi T., Arita M., Tomobuchi Y., Hamada M., Hano T., Nishio I. Effects of locally administered argatroban on restenosis after balloon angioplasty. Experimental and clinical study Clin Exp Pharmacol Physiol. 24:1997;800-806.
169. Brill-Edwards P., Van Ryn-McKenna J., Cai L., Ofosu F.A., Buchanan M.R. Prevention of thrombus growth by antithrombin III-dependent and two direct thrombin inhibitors in rabbits. Implications for antithrombotic therapy Thromb Haemost. 68:1992;424-427.
170. Bagdy D., Szabo G., Barabas E., Bajusz S. Inhibition by D-Me-Phe-Pro-Arg-H (GYKI-14766) of thrombus growth in experimental models of thrombosis. Thromb Haemost. 68:1992;125-129.
171. Gustafsson D., Elg M., Lenfors S., Börjesson I., Teger-Nilsson A.-C. Effects of inogatran, a new low-molecular weight thrombin inhibitor, in rat models of venous and arterial thrombosis, thrombolysis and bleeding time. Blood Coagul Fibrinolysis. 7:1996;69-79.
172. Rebello S.S., Miller B.V., Basler G.C., Lucchesi B.R. CVS-1123, a direct thrombin inhibitor, prevents occlusive arterial and venous thrombosis in a canine model of vascular injury. J Cardiovasc Pharmacol. 29:1997;240-249.
173. Schumacher W.A., Heran C.H., Steinbacher T.E. Low-molecluar-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J Cardiovasc Pharmacol. 28:1996;19-25.
174. Sudo Y., Lucchesi B.R. Antithrombotic effect of GYKI-14766 in a canine model of arterial and venous rethrombosis. A comparison with heparin J Cardiovasc Pharmacol. 27:1996;545-555.
175. Finkle C.D., St Pierre A., Leblond L., Deschenes I., Dimaio J., Winocour P.D. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosis - comparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb Haemost. 79:1998;431-438.
176. Lyle E.M., Lewis S.D., Lehman E.D., Gardell S.J., Motzel S.L., Lynch J.J. Assessment of thrombin inhibitor efficacy in a novel rabbit model of simultaneous arterial and venous thrombosis. Thromb Haemost. 79:1998;656-662.
177. 2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation. 86:1992;1993-1999.
178. Imura Y., Stassen J., Collen D. Comparative antithrombotic effects of heparin, recombinant hirudin and argatroban in a hamster femoral vein platelet-rich mural thrombosis model. J Pharmacol Exp Ther. 261:1992;895-898.
179. Imura Y., Stassen J.-M., Vreys I., Lesaffre E., Gold H.K., Collen D. Synergistic antithrombotic properties of G4120, a RGD-containing synthetic peptide, and argatroban, a synthetic thrombin inhibitor, in a hamster femoral vein platelet-rich thrombosis model. Thromb Haemost. 68:1992;336-340.
180. Pratico D., Murphy N.P., Fitzgerald D.J. Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo. Evidence that thrombin mediates platelet aggregation and subsequent thromboxane A(2) formation during coronary thrombolysis J Pharmacol Exp Ther. 281:1997;1178-1185.
181. Shetler T.J., Crowe V.G., Bailey B.D., Jackson C.V. Antithrombotic assessment of the effects of combination therapy with the anticoagulants efegatran and heparin and the glycoprotein IIb-IIIa platelet receptor antagonist 7E3 in a canine model of coronary artery thrombosis. Circulation. 94:1996;1719-1725.
182. Yasuda S., Gold H.K., Yaoita H., Leinbach R.C., Guerrero J.L., Jang I.-K., Holt R., Fallon J.T., Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery perfusion, reocclusion, and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol. 16:1990;714-722.
183. Jang I.-K., Gold H.K., Ziskind A.A., Leinbach R.C., Fallon J.T., Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation. 81:1990;219-225.
184. Schumacher W.A., Steinbacher T.E., Heran C.H., Megill J.R., Durham S.K. Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Hae- most. 69:1993;509-514.
185. Duval N., Lunven C., O'Brien D.P., Grosset A., O'Connor S.E., Berry C.N. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow. Comparison with heparin Br J Pharmacol. 118:1996;727-733.
186. Jackson C.V., Crowe V.G., Frank J.D., Wilson H.C., Coffmann W.J., Utterback B.G., Jakubowski J.A., Smith G.F. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther. 261:1992;546-552.
187. Roux S., Tschopp T., Baumgartner H.R. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis. Comparison with an ex vivo annular perfusion chamber model J Pharmacol Exp Ther. 277:1996;71-78.
188. Uriuda Y., Wang Q.-D., Grip L., Ryden L., Sjöqusit P.-O., Mattsson C. Antithrombotic activity of inogatran, a new low-molecular-weight inhibitor of thrombin, in a closed-chest porcine model of coronary artery thrombosis. Cardiovasc Res. 32:1996;320-327.
189. Cousins G.R., Friedrichs G.S., Sudo Y., Rebello S.S., Rote W.E., Vlasuk G.P., Nolan T.G., Mendoza C., Lucchesi B.R. Orally effective CVS-1123 prevents coronary artery thrombosis in the conscious dog. Circulation. 94:1996;1705-1712.
190. Mattsson C., Björkman J.-A., Ulvinge J.-C. Melagatran, hirudin and heparin as adjuncts to tissue-type plasminogen activator in a canine model of coronary artery thrombolysis. Fibrinolysis Proteolysis. 11:1997;121-128.
191. Glusa E., Bretschneider E., Paintz M. Contractile effects of thrombin in porcine pulmonary arteries and the influence of thrombin inhibitors. Naunyn-Schmiedeberg's Arch Pharmacol. 349:1994;101-106.
192. Kovacs A., Barabas E., Aranyi P., Rabloczky G. Thrombin inhibitor (GYKI-14766) prevents thrombin induced vascular effects. Eur J Pharmacol. 183:1990;1844-1845.
193. Glusa E., Brauns H., Stocker K. Endothelium-dependent relaxant effect of thrombocytin, a serine proteinase from Bothrops atrox snake venom, on isolated pig coronary arteries. Toxicon. 29:1991;725-732.
194. Winn M.J., Ku D.D., Nelson J.M. Inhibition of thrombin-induced endothelium-dependent relaxation after coronary ischemia in the dog. Possible role of the coagulation cascade J Cardiovasc Pharmacol. 18:1991;68-76.
195. Kawai H., Yuki S., Sugimoto J., Tamao Y. Effects of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther. 278:1996;780-785.
196. Kawai H., Uemura K., Nakashima M. Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J Pharmacol. 69:1995;143-148.
197. Umemura K., Kawai H., Ishihara H., Nakashima M. Inhibitory effect of clopidogrel, vapiprost and argatroban on the middle cerebral artery thrombosis in the rat. Jpn J Pharmacol. 76:1995;253-258.
198. Chomiak P.N., Walenga J.M., Koza M.J., Reilly T.M., Turlapathy P., Pifarre R. Investigation of a thrombin inhibitor peptide as an alternative to heparin in cardiopulmonary bypass. Circulation. 88:1993;407-412.
199. Walenga J.M., Koza M.J., Pifarre R. Potential use of new thrombin inhibitors and low-molecular-weight heparins as anticoagulants in cardiopulmonary bypass surgery. Pifarre R. Anticoagulation, hemostasis, and blood preservation in cardiovascular surgery. 1993;343-352 Hanley and Belfus, Philadelphia.
200. Chen L.Y., Nichols W.W., Mattsson C., Teger-Nilsson A.-C., Saldeen T.G.P., Mehta J.L. Inogatran, a novel direct low molecular weight thrombin inhibitor, given with, but not after, tissue-plasminogen, improves thrombolysis. J Pharmacol Exp Ther. 277:1996;1276-1283.
201. Lenfors S., Marberg L., Wikström S., Jonsson U., Eriksson A.W., Gustafsson D. A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail - thrombolysis experiments with specific thrombin inhibition. Blood Coagul Fibrinolysis. 4:1993;263-271.
202. Mellott M.J., Connolly T.M., York S.J., Bush L.R. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral artery thrombosis. Thromb Haemost. 64:1990;526-534.
203. Jackson C.V., Wilson H.C., Crowe V.G., Shuman R.T., Gesellchen P.D. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis. Comparison with heparin in a canine model of coronary artery thrombosis J Cardiovasc Pharmacol. 21:1993;587-594.
204. Chen L.Y., Nichols W.W., Mattsson C., Teger-Nilsson A.-C., Wallin R., Saldeen T.G.P. Aspirin does not potentiate effect of suboptimal dose of the thrombin inhibitor inogatran during coronary thrombolysis. Cardiovasc Res. 30:1995;866-874.
205. Klement P., Borm A., Hirsh J., Maraganore J., Wilson G., Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost. 68:1992;64-68.
206. Schneider J. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected Saruplase (r-scu-PA) in rabbit femoral artery thrombosis. Thromb Res. 64:1991;677-689.
207. Jang I.-K., Gold H.K., Leinbach R.C., Fallon J.T., Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res. 67:1990;1552-1561.
208. Gold H.K., Yasuda T., Jang I.K., Guerrero J.L., Fallon J.T., Leinbach R.C., Collen D. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. Circulation. 83(Suppl 6):1991;26-40.
209. Valji K., Arun K., Bookstein J.J. Use of a direct thrombin inhibitor (argatroban) during pulse-spray thrombolysis in experimental thrombosis. J Vasc Interv Radiol. 6:1995;91-95.
210. Nishiyama H., Umemura K., Saniabadi A.R., Takiguchi Y., Uematsu T., Nakashima M. Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model. Eur J Pharmacol. 264:1994;191-198.
211. Uriuda Y., Wang Q.-D., Hatori N., Nordlander R., Sjöqusit P.-O., Mattsson C., Ryden L. Coronary thrombosis/thrombolysis in pigs. Effects of heparin, ASA, and the thrombin inhibitor inogatran J Pharmacol Toxicol Methods. 39:1998;81-89.
212. Bajzar L., Manuel R., Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem. 270:1995;14477-14484.
213. Oltrona L., Eisenberg P.R., Abendschein D.R., Rubin B.G. Efficacy of local inhibition of procoagulant activity associated with small-diameter prosthetic vascular grafts. J Vasc Surg. 24:1996;624-631.
214. Terada S., Suzuki K., Nozaki M., Okano T., Takemura N. Anti-thrombogenic effects of 2-hydroxy-ethylmethacrylate-styrene block copolymer and argatroban in synthetic small-caliber vascular grafts in a rabbit inferior vena cava model. J Reconstr Microsurg. 13:1997;9-16.
215. Mousa S.A., Bozarth J.M., Edwards S., Carroll T., Barrett J. Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. Coron Artery Dis. 9:1998;131-141.
216. Carteaux J.P., Gast A., Tschopp T.B., Roux S. Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental thrombosis. Circulation. 91:1995;1568-1574.
217. Berry C.N., Lunven C., Girardot C., Lechaire I., Girard D., Charles M.-C., Ferrari P., O'Brien D.P. Ecarin clotting time. a predictive coagulation assay for the antithrombotic activity of argatroban in the rat Thromb Haemost. 79:1998;228-233.
218. Sato K., Taniuchi Y., Kawasaki T., Hirayama F., Koshio H., Matsumoto Y. Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats. Eur J Pharmacol. 347:1998;231-236.
219. Schaeffer P., Mares A.M., Dol F., Bono F., Herbert J.M. Coagulation factor Xa induces endothelium-dependent relaxations in rat aorta. Circ Res. 81:1997;824-828.
220. Herbert J., Bono F., Herault J.P., Avril C., Dol F., Mares A., Schaeffer P. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo. J Clin Invest. 101:1998;993-1000.
221. Kawasaki T., Sato K., Hirayama F., Koshio H., Taniuchi Y., Matsumoto Y. Effect of a synthetic factor Xa inhibitor, YM-60828, on blood vessel patency in combination with a thrombolytic agent and on blood loss from the operation site in a rat model of arterial thrombosis. Thromb Haemost. 79:1998;859-864.
222. Sato K., Kawasaki T., Hisamichi N., Taniuchi Y., Hirayama R., Koshio H., Ichihara M., Matsumoto Y. Antithrombotic effects of YM-60828 in three thrombosis models in guinea pigs. Eur J Pharmacol. 350:1998;87-91.
223. Sato K., Kaku S., Hirayama F., Koshio H., Matsumoto Y., Kawasaki T., Iizumi Y. Antithrombotic effect of YM-75466 is separated from its effect on bleeding time and coagulation time. Eur J Pharmacol. 352:1998;59-63.
224. Rasky K., Patfalusi M., Vereczkey L. Chromogen-substrate assay - as a tool for monitoring a new thrombin inhibitor. Acta Pharmacol Hung. 63:1993;3-12.
225. Wagenvoord R.J., Hendrix H.H., Kolde H.J., Hemker H.C. Development of a rapid and sensitive chromogenic heparin assay for clinical use. Haemostasis. 23:1993;26-37.
226. Mitchell T.J., Knabb R., Christ D.D., Farmer A.R., Reilly T.M. Analysis of the thrombin inhibitor DuP 714 by an enzyme-linked immunosorbent assay. Blood Coagul Fibrinolysis. 5:1994;517-521.
227. Mendoza C.B., Dixon S.A., Lods M.M., Ma M.G., Nguyen K.T., Nutt R.F., Tran H.S., Nolan T.G. Quantitation of an orally available thrombin inhibitor in rat, monkey and human plasma and in human urine by high-performance liquid chromatography and fluorescent post-column derivatization of arginine. J Chromatogr A. 762:1997;299-310.
228. Clarke R.J., Mayo G., FitzGerald G.A., Fitzgerald D.J. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation. 83:1991;1510-1518.
229. Hauptmann J., Paintz M., Kaiser B., Markwardt F. Reduction of a benzamidoxime derivative to the corresponding amidine in vivo and in vitro. Pharmazie. 43:1988;559-560.
230. Paintz M., Richter M., Hauptmann J. HPLC determination of the synthetic thrombin inhibitor Nα-(2-naphthylsulfonylglycyl)-4-amidinophenylalanine piperidide in biological material. Pharmazie. 42:1987;346.
231. Hauptmann J., Stürzebecher J. Influence of indocyanine green on plasma disappearance and biliary excretion of a synthetic thrombin inhibitor of the 3-amidinophenylalanine piperazide-type in rats. Pharm Res. 15:1998;751-754.
232. Murayama N., Sudo K. High-performance liquid chromatographic method for determination of DX-9065a, a novel anticoagulant, in human urine and feces using cation-exchange solid-phase extraction. J Chromatogr B Biomed Appl. 692:1997;389-396.
233. Murayama N., Tanaka S., Kikuchi T., Nakaoka M., Sudo K. Radioimmunoassay method for DX-9065a, an anticoagulant agent. Development, evaluation and application to human plasma. J Pharm Biomed Anal. 14:1996;1435-1445.
234. Eriksson U.G., Renberg L., Bredberg U., Teger-Nilsson A.-C., Regardh C.G. Animal pharmacokinetics of inogatran, a low-molecular-weight thrombin inhibitor with potential use as an antithrombotic drug. Biopharm Drug Dispos. 19:1998;55-64.
235. Bounameaux H., Ehringer H., Hulting J., Rasche H., Rapold H.J., Zultak M. An exploratory trial of two dosages of a novel synthetic thrombin inhibitor (napsagatran, Ro 46-6240) compared with unfractionated heparin for treatment of proximal deep-vein thrombosis. Results of the European Multicenter ADVENT trial. Thromb Haemost. 78:1997;997-1002.
236. TRIM Study Group A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients. A double blind randomized, dose finding study Eur Heart J. 18:1997;1416-1425.
237. Hauptmann J., Kaiser B. In vitro and in vivo comparison of arginine- and benzamidinederived highly potent synthetic thrombin inhibitors. Pharmazie. 46:1991;57-58.
238. Stüber W., Koschinsky R., Reers M., Hoffmann D., Czech J., Dickneite G. Preparation and evaluation of PEG-bound thrombin inhibitors based on 4-amidinophenylalanine. Peptide Res. 8:1995;78-85.
239. Gold H.K., Torres F.W., Garabedian H.D., Werner W., Jang I., Khan A., Hagstrom J.N., Yasuda T., Leinbach R.C., Newell J.B., Bovill E.G., Stump D.C., Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 21:1993;1039-1047.
240. 2Cl in baboons. Blood. 81:1993;1762-1770.
241. Heath T.G., Mooney J.P., Broersma R. Narrow-bore liquid chromatography-tandem mass spectrometry with simultaneous radioactivity monitoring for partially characterizing the biliary metabolites of an arginine fluoralkyl ketone analog of D-MePhe-Pro-Arg, a potent thrombin inhibitor. J Chromatogr, B: Biomed Sci Appl. 688:1997;281-289.
242. Kaiser B., Hauptmann J., Markwardt F. Studies on toxicity and pharmacokinetics of the synthetic thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine nitrile. Pharmazie. 46:1991;131-134.
243. Gabriel B., Stubbs M.T., Bergner A., Hauptmann J., Bode W., Stürzebecher J., Moroder L. Structure-based design of benzamidine-type inhibitors of factor Xa. J Med Chem. 41:1998;4240-4251.
244. Barry M., Gibbons S., Back D., Mulcahy F. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 32:1997;194-209.
245. 1. J Med Chem. 39:1996;4527-4530.
246. Eckhardt U., Stüber W., Dickneite G., Reers M., Petzinger E. First-pass elimination of a peptidomimetic thrombin inhibitor is due to carrier-mediated uptake by the liver - interaction with bile acid transport systems. Biochem Pharmacol. 52:1996;85-96.
247. Tapparelli C., Metternich R., Gfellner P., Gafner P., Powling M. Antithrombotic activity in vivo of SDZ 217-766, a low molecular weight thrombin inhibitor in comparison to heparin. Thromb Haemost. 73:1995;641-647.
248. Bagdy D., Barabas E., Szabo G., Bajusz S., Szell E. In vivo anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H and D-Me-Phe-Pro-Arg-H. Thromb Haemost. 67:1992;357-365.
249. Hussain M.A., Knabb R., Aungst B.J., Kettner C. Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats. Peptides. 12:1991;1153-1154.
250. Eckhardt U., Horz J.A., Petzinger E., Stüber W., Reers M., Dickneite G., Daniel H., Wagener M., Hagenbuch B., Stieger B., Meier P.J. The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat-liver organic anion-transporting polypeptide. Hepatology. 24:1996;380-384.
251. Walter E., Kissel T., Reers M., Dickneite G., Hoffmann D., Stüber W. Transepithe- lial transport properties of peptidomimetic thrombin inhibitors in monolayer of human intestinal cell line (Caco-2) and their correlation to in vivo data. Pharm Res. 12:1995;360-365.
252. Bajusz S., Barabas E., Fauszt I., Feher A., Horvath G., Juhasz A., Szabo G.A., Szell E. Active site-directed thrombin inhibitors. α-hydroxyacyl-prolyl-arginals. New orally active stable analogues of D-Phe-Pro-Arg-H Bioorg Med Chem. 3:1995;1079-1089.
253. Tamura S.Y., Semple J.E., Reiner J.E., Goldman E.A., Brunck T.K., Lim-Wilby M.S., Carpenter S.H., Rote W.E., Oldeshulte G.L., Richard B.M., Nutt R.F., Ripka W.C. Design and synthesis of a novel class of thrombin inhibitors incorporating heterocyclic dipeptide surrogates. Bioorg Med Chem Lett. 7:1997;1543-1548.
254. Hauptmann J., Markwardt F., Richter M. Tierexperimentelle Untersuchungen zur Pharmakokinetik von Nα-Tosyl-3-amidinophe-nylalaninpiperidid (TAPAP), einem neuen Thrombininhibitor. Pharmazie. 37:1982;430-433.
255. Kaiser B., Hauptmann J., Weiss A., Markwardt F. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed Biochim Acta. 44:1985;1201-1210.
256. Hauptmann J., Kaiser B., Paintz M., Markwardt F. Biliary excretion of synthetic benzamidine-type thrombin inhibitors in rabbits and rats. Biomed Biochim Acta. 46:1987;445-453.
257. Hauptmann J., Kaiser B., Paintz M., Markwardt F. Pharmacological characterization of a new structural variant of 4-amidinophenylalanine amide-type synthetic thrombin inhibitor. Pharmazie. 44:1989;282-284.
258. Hauptmann J., Etemad F., Ziegler K., Stürzebecher J., Petzinger E. Uptake in rat hepatocytes and hepatic clearance in vivo of cationic amidinophenylalanine-derived peptidomimetic thrombin inhibitors [Abstract]. Naunyn-Schmiedeberg's Arch Pharmacol. 355(Suppl. 4):1997;R8.
259. Hursting M.J., Becker J.C., Joffrion J.L., Knappenberger G.D., Schwarz R.P. Effect of hepatic function on the pharmacokinetics and pharmacodynamics of argatroban. Thromb Haemost. Suppl):1997;493-494.
260. Reers M., Koschinsky R., Dickneite G., Hoffmann D., Czech J., Stüber W. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. J Enzyme Inhibit. 9:1995;61-72.
261. Schwarz R.P., Becker J.C., Brooks R.L., Hursting M.J., Joffrion J.L., Knappenberger G.D., Kogan T.P., Kogan P.W., McKinney A.A. The preclinical and clinical pharmacology of novastan (argatroban). A small-molecule, direct thrombin inhibitor Clin Appl Thromb/Hemost. 3:1997;1-15.
262. Willerson J.T., Casscells W. Thrombin inhibitors in unstable angina. Rebound or continuation of angina after argatroban withdrawal? J Am Coll Cardiol. 21:1993;1048-1051.
263. Suzuki A., Sakamoto S., Adachi K., Mizutani K., Koide M., Ohga N., Miki T., Matsuo T. Effect of argatroban on thrombus formation during acute coronary occlusion after balloon angioplasty. Thromb Res. 77:1995;369-373.
264. Sakamoto S., Hirase T., Suzuki S., Tsukamoto T., Miki T., Yamada T., Matsuo T. Inhibitory effect of argatroban on thrombin-antithrombin III complex after percutaneous transluminal angioplasty. Thromb Haemost. 74:1995;801-802.
265. Herrman J.P.R., Suryapranata H., den Heijer P., Gabriel L., Kutryk M.J.B., Serruys P.W. Argatroban during percutaneous transluminal angioplasty; results of a dose verification study. J Thromb Thrombolysis. 3:1996;367-375.
266. Vermeer F., Vahanina A., Fels P.W., Besse P., Radzik D., Simoons M.L. Intravenous argatroban versus heparin as co-medication to alteplase in the treatment of acute myocardial infarction; preliminary results of the ARGAMI pilot study. J Am Coll Cardiol. 29:1997;185-186.
267. Lewis B.E., Walenga J.M., Pifarre R., Fareed J. Argatroban in the management of patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Pifarre R. New anticoagulants for the cardiovascular patient. 1997;223-229 Hanley and Belfus, Philadelphia.
268. Lewis B.E., Walenga J.M., Wallis D.E. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin Thromb Hemost. 23:1997;197-202.
269. Matsuo T., Koide M., Kario K. Application of argatroban, direct thrombin inhibitor, in heparin-intolerant patients requiring extracorporeal circulation. Artif Organs. 21:1997;1035-1038.
270. Lewis B.E., Grassman E.D., Wrona L., Rangel Y. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis. 8:1997;54-58.
271. Matsuo T., Kario K., Chikahira Y., Nakao K., Yamada T. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haemat. 82:1992;627-629.
272. Suzuki S., Sakamoto S., Koide M., Kobayashi H., Matsuo M., Shimano C., Matsuo T. Effective anticoagulation by argatroban during immunoadsorption therapy for malignant rheumatoid arthritis with a high polymorphonuclear leucocyte elastase level. Thromb Res. 80:1995;93-98.
273. Lewis B.E., Johnson S.A., Grassman E.D., Wrona L.L. Argatroban as an anticoagulant for coronary procedures in patients with HIT antibody. Pifarre R. New anticoagulants in the cardio-vascular patient. 1997;301-308 Hanley and Belfus, Philadelphia.
274. Andersen K., Dellborg M., Emanuelsson H., Grip L., Swedberg K. Thrombin inhibition with inogatran for unstable angina pectoris. Evidence for reactivated ischaemia after cessation of short-term treatment Coron Artery Dis. 7:1996;673-681.
275. Andersen K., Dellborg M. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease. Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. Am J Cardiol. 81:1998;939-944.
276. Antman E.M. Another chapter of the antithrombin story has been written. Eur Heart J. 18:1997;1365-1367.
277. Kher A., Al Dieri R., Hemker H.C., Beguin S. Laboratory assessment of antithrombotic therapy. What tests and if so why? Haemostasis. 27:1997;211-218.